Key Opinion Leaders are physicians or scientists whose clinical reputation, publications, and society leadership influence peer adoption of medical technologies. Engaged through advisory boards, speaker programs, clinical research, and product development input. Companies engage KOLs as consultants, trial investigators, speakers or advisory board members. Payments must be at fair market value, for legitimate services, and reported under the Sunshine Act. KOL input helps shape trial design, training and adoption.

Why it matters

KOL strategy is foundational to MedTech launches - early KOL involvement shapes trial design, guideline language, and adoption velocity. Sunshine Act reporting requirements apply to all transfers of value.

Common pitfalls

•Failing to report all transfers of value to KOLs can result in significant penalties under the Physician Payments Sunshine Act.
•Engaging KOLs in activities that could be perceived as off-label promotion, even if unintended, can lead to regulatory enforcement actions.
•Not having clear, documented agreements and scopes of work for KOL engagements can lead to compliance issues and reputational damage.
•Using KOLs to promote unapproved uses of medical devices directly violates FDA regulations on promotion and advertising.
•Providing excessive or inappropriate gifts or payments to KOLs can be considered a kickback and violate anti-kickback statutes.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.